

**Recombinant Human sTRAIL/Apo2L**  
**Catalog # PBG10459****Specification**

---

**Recombinant Human sTRAIL/Apo2L - Product Information****Recombinant Human sTRAIL/Apo2L - Additional Information****Description**

TRAIL/Apo2L is a cytotoxic protein, which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL induced apoptosis is achieved through binding to two death-signaling receptors, DR4 and DR5. These receptors belong to the TNFR superfamily of transmembrane proteins and contain a cytoplasmic "death domain", which activates the cell's apoptotic machinery. Recombinant human soluble TRAIL/Apo2L is a 168 amino acid polypeptide (19.6 kDa), consisting of the TNF homologous portion of the extracellular domain of the full length TRAIL/Apo2L protein.

**BiologicalActivity**

**Assay#1:** Determined by its ability to induce apoptotic cell death in TRAIL-sensitive U343MG cells. The expected **ED<sub>50</sub>** for this effect is 1.0-3.0 ng/ml.   
**Assay#2:** Measured by its ability to induce apoptosis in LN-18 cells (human glioblastoma cells). The expected **ED<sub>50</sub>** for this effect is 0.8 - 2.0 ng/ml.

**Authenticity**

Verified by N-terminal and Mass Spectrometry analyses (when applicable).

**Endotoxin**

Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg).

**Protein Content**

Verified by UV Spectroscopy and/or SDS-PAGE gel.

**Storage**

-20°C

**Precautions**

Recombinant Human sTRAIL/Apo2L is for research use only and not for use in diagnostic or therapeutic procedures.

**Recombinant Human sTRAIL/Apo2L - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)

- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**Recombinant Human sTRAIL/Apo2L - Images**